Skip to main content
Log in

Abnormalities of lipid metabolism and methods of their correction in patients with glomerulonephritis

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

The results of integrated estimations of a complex of lipid indices are presented. Their abnormalities are considered to be atherosclerosis risk factors in the evolution of glomerulonephritis and its different variants, types and stages. The quantitative and qualitative peculiarities of the indicated abnormalities are revealed, in particular, their major expressiveness in chronic form, nephrotic variant and in the stage of renal failure.

Two aspects of correction of actual abnormalities are singled out: 1. indirect, i.e. treatment of the renal pathologic process with preparation of pathogenetic therapy (glucocorticoids, indomethacin), and 2. direct, i.e. with medications exerting a corrective influence on lipid metabolism (clofibrate, nicotinic acid, curantil).

The selection of corrective methods is determined by the stage of disease and by the character of the changes in lipid metabolism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Bagdade, J. D.: Mechanism of hyperlipidemia in chronic uremia.Circulation, 52, Suppl. 2, 269 (1975).

    Google Scholar 

  2. Bagdade, J. D.: Effects of clofibrate on plasma lipids and high-density lipoprotein levels in renal allograft recipients.Clin. Nephrol., 12, 85 (1979).

    Google Scholar 

  3. Campanaci, L.: Dislipidemia e aterosclerosis accelerata nell uremia chronica.J. Clin. Med., 59, 318 (1978).

    Google Scholar 

  4. David, K.: Renal disease and hyperlipidemia. IV. Intern. Congr. of Nephrology, Firenze 1975, p. 648.

  5. Giulio, R.: Clofibrate treatment of hyperlipidemia in chronic renal failure.Clin. Nephrol., 8, 504 (1977).

    PubMed  Google Scholar 

  6. Melman, N. Ya.: Some mechanisms of hyperdyslipidemia in evolution of chronic renal failure and the ways of their correction. Treatment of chronic nephritis. Symposium of Nephrologists of Socialist Countries. Abstracts. 1977, p. 16.

  7. Pyrig, L. A., Melman, N. Ya., Shinkarenko, N. R.: Some indices of lipid metabolism in patients with chronic renal failure under the conditions of systemic hemodialysis.Urologia i nephrologia, 3, 51 (1979).

    Google Scholar 

  8. Pyrig, L. A., Melman, N. Ya., Petrun, N. M.: Medicamental correction of lipid metabolism abnormalities in patients with glomerulonephritis.Klinicheskaya medicina, 2, 49 (1981).

    Google Scholar 

  9. Pyrig, L. A., Melman, N. Ya.: Methodologic basis of glomerulonephritis classification. 18th All-Union Congress of Therapists. Part II. Moscow 1981, p. 439.

  10. Tareev, E. M., Ermolenko, V. M., Nikiforova, N. V.: Fat metabolism abnormality in chronic renal failure.Klinicheskaya medicina, 1, 4 (1976).

    Google Scholar 

  11. Shultsev, G. P., Mutina, E. S.: Alterations of lipid metabolism in some diseases.Therapeuticheskii archiv, 4, 35 (1969).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pyrig, L.A., Melman, N.Y., Petrun, N.M. et al. Abnormalities of lipid metabolism and methods of their correction in patients with glomerulonephritis. International Urology and Nephrology 16, 361–367 (1984). https://doi.org/10.1007/BF02081872

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02081872

Keywords

Navigation